GlucoTrack Company Leadership
| GCTK Stock | USD 6.31 0.31 5.17% |
GlucoTrack employs about 11 people. The company is managed by 11 executives with a total tenure of roughly 26 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Inspection of GlucoTrack's management performance can provide insight into the company performance.
GlucoTrack | Build AI portfolio with GlucoTrack Stock |
GlucoTrack Management Team Effectiveness
The company has return on total asset (ROA) of (1.6101) % which means that it has lost $1.6101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9434) %, meaning that it created substantial loss on money invested by shareholders. GlucoTrack's management efficiency ratios could be used to measure how well GlucoTrack manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlucoTrack's Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 18.5 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 4 M.The value of Common Stock Shares Outstanding is expected to slide to about 232.9 K. The value of Net Loss is expected to slide to about (5.4 M)
GlucoTrack Workforce Comparison
GlucoTrack is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 282,683. GlucoTrack adds roughly 11.0 in number of employees claiming only tiny portion of equities under Health Care industry.
GlucoTrack Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlucoTrack insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlucoTrack's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, GlucoTrack insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Paul Goode few days ago Acquisition by Paul Goode of 796 shares of GlucoTrack at 5.6 subject to Rule 16b-3 | ||
Balo Andrew K over a week ago Insider Trading | ||
Fischell Robert over three months ago Acquisition by Fischell Robert of 1498 shares of GlucoTrack subject to Rule 16b-3 | ||
Seff Leslie over three months ago Acquisition by Seff Leslie of 22727 shares of GlucoTrack at 1.98 subject to Rule 16b-3 | ||
Paul Goode over three months ago Acquisition by Paul Goode of 796 shares of GlucoTrack subject to Rule 16b-3 | ||
Peter Wulff over three months ago Insider Trading | ||
Darivoff Philip over six months ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack at 5.8 subject to Rule 16b-3 | ||
Paul Goode over six months ago Acquisition by Paul Goode of 42000 shares of GlucoTrack at 4.95 subject to Rule 16b-3 |
GlucoTrack Notable Stakeholders
A GlucoTrack stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GlucoTrack often face trade-offs trying to please all of them. GlucoTrack's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GlucoTrack's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Erez BenZvi | GM Product | Profile | |
| Drinda Benjamin | Vice Marketing | Profile | |
| Paul Goode | Chief Officer | Profile | |
| MScEE MBA | Chairman CoFounder | Profile | |
| Mark Tapsak | Vice Technology | Profile | |
| Esq CPA | Chief Officer | Profile | |
| David BA | CoFounder | Profile | |
| Peter Wulff | Chief Officer | Profile | |
| Vincent Wong | Vice Operations | Profile | |
| James Thrower | Vice Engineering | Profile | |
| James Cardwell | Chief Officer | Profile |
About GlucoTrack Management Performance
The success or failure of an entity such as GlucoTrack often depends on how effective the management is. GlucoTrack management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GlucoTrack management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GlucoTrack management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel. Glucotrack operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.
GlucoTrack Workforce Analysis
Traditionally, organizations such as GlucoTrack use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GlucoTrack within its industry.GlucoTrack Manpower Efficiency
Return on GlucoTrack Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.1M | |
| Net Loss Per Executive | 2.1M | |
| Working Capital Per Employee | 408.5K | |
| Working Capital Per Executive | 408.5K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.